Back to Journals » Hepatic Medicine: Evidence and Research » Volume 7

Interferon-free combination therapies for the treatment of hepatitis C: current insights

Authors Holmes J, Thompson A

Received 7 August 2015

Accepted for publication 27 August 2015

Published 2 November 2015 Volume 2015:7 Pages 51—70

DOI https://doi.org/10.2147/HMER.S55864

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Sathish kumar Natarajan

Peer reviewer comments 3

Editor who approved publication: Dr Gerry Lake-Bakaar


Jacinta A Holmes, Alexander J Thompson

Department of Gastroenterology, St Vincent's Hospital, University of Melbourne, Fitzroy, Victoria, Australia

Abstract: The hepatitis C virus (HCV) treatment landscape has rapidly changed over the past 5 years. The development of direct-acting antiviral (DAA) agents that specifically target various steps in the HCV lifecycle has revolutionized therapeutic options for patients with HCV, with the development of highly effective and well-tolerated oral interferon-free regimens. There are many DAAs that are currently in development or have recently been approved, which target different nonstructural HCV proteins and host targets that are essential for HCV replication. This review will focus on the different classes of DAAs and the various combinations that are in advanced development for the treatment of chronic HCV infection and will focus on the different regimens in specific patient populations.

Keywords: interferon-free, direct-acting antivirals, HCV therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]